A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 361 participants.
Also called NCT05362110
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 361 participants
- Registry
-
NCT05362110
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05362110. Randomized; double masking; primary purpose treatment. Start 2022-05-16 (actual); primary completion 2023-06-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
- Acronym
- HM_APOLLO
- Condition
- Hypertension
- Intervention (Drug)
- HCP1803-3
- Intervention (Drug)
- RLD2002
- Intervention (Drug)
- HPP2003-3
- Intervention (Drug)
- HPP2004
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct05362110- Content hash
e3484d4cb5e23a1901dea173e77bcf6b164f2f470826f6b3040224e9d57bf553